摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-溴-2-氯-4-三氟甲氧基苯 | 892845-59-9

中文名称
1-溴-2-氯-4-三氟甲氧基苯
中文别名
1-溴-2-氯-4-(三氟甲氧基)苯;4-溴-3-氯三氟甲氧基苯
英文名称
1-bromo-2-chloro-4-(trifluoromethoxy)benzene
英文别名
——
1-溴-2-氯-4-三氟甲氧基苯化学式
CAS
892845-59-9
化学式
C7H3BrClF3O
mdl
MFCD11111892
分子量
275.452
InChiKey
RRRFVMOJVRRZMM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2909309090
  • 危险性防范说明:
    P261,P280,P301+P312,P302+P352,P305+P351+P338
  • 危险性描述:
    H302,H315,H320,H335
  • 储存条件:
    应存放在室温、避光且处于惰性气体中的环境里。

SDS

SDS:ffeb47e7db1c1ca0dc3e7a7359aa6070
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1-Bromo-2-chloro-4-(trifluoromethoxy)benzene
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1-Bromo-2-chloro-4-(trifluoromethoxy)benzene
CAS number: 892845-59-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H3BrClF3O
Molecular weight: 275.5

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen fluoride, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] IMIDAZOLE-BASED ANTIMICROBIAL AGENTS<br/>[FR] AGENTS ANTIMICROBIENS À BASE D'IMIDAZOLE
    申请人:PROCOMCURE BIOTECH GMBH
    公开号:WO2016087618A1
    公开(公告)日:2016-06-09
    The present invention relates to novel therapeutic agents suitable for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes.
    本发明涉及新型治疗剂,适用于治疗哺乳动物疾病,特别是适用于治疗哺乳动物微生物感染的新型治疗剂。本发明还涉及包含上述剂的药物组合物在治疗哺乳动物的医疗状况中的使用,特别是在治疗微生物感染中的使用。本发明的剂和药物组合物在治疗与抗生素耐药微生物相关的疾病方面具有特殊意义。
  • Pyrazolyl-Based Carboxamides II
    申请人:Grünenthal GmbH
    公开号:US20140194452A1
    公开(公告)日:2014-07-10
    The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.
    这项发明涉及以吡唑基为基础的羧酰胺化合物,其作为ICRAC抑制剂有用,以及含有这些化合物的药物组合物,以及这些化合物在治疗和/或预防疾病和/或疾病中的用途,特别是炎症性疾病和/或炎症性疾病。
  • [EN] HETEROCYCLIC DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS<br/>[FR] DÉRIVÉS HÉTÉROCYLCIQUES UTILISÉS EN TANT QUE BLOQUEURS NAV1.7 ET NAV1.8
    申请人:RAQUALIA PHARMA INC
    公开号:WO2020138271A1
    公开(公告)日:2020-07-02
    The present invention relates to heterocyclic derivatives which have blocking activities of voltage gated sodium channels as the Nav1.7 and Nav1.8 channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.
    本发明涉及具有阻断活性的杂环衍生物,其作用于Nav1.7和Nav1.8通道的电压门控钠通道,并且在处理或预防涉及电压门控钠通道的疾病和疾病方面具有用途。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病方面的用途。
  • [EN] NOVEL IMIDAZOLE-BASED HETEROCYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES À BASE D'IMIDAZOLE
    申请人:PROCOMCURE BIOTECH GMBH
    公开号:WO2016087615A1
    公开(公告)日:2016-06-09
    The present invention relates to novel compounds of formula (I) suitable e.g. as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The present invention also relates to processes for making said agents.
    本发明涉及一种新型化合物,其化学式为(I),适用于作为治疗剂用于治疗哺乳动物疾病,特别是适用于治疗哺乳动物微生物感染的新型治疗剂。本发明还涉及包含所述治疗剂的药物组合物在治疗哺乳动物的医疗状况中的使用,特别是在治疗微生物感染方面的使用。本发明的治疗剂和药物组合物在治疗与抗生素耐药微生物相关的疾病方面具有特殊的相关性。本发明还涉及制备所述治疗剂的方法。
  • INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME
    申请人:THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    公开号:US20190308947A1
    公开(公告)日:2019-10-10
    Disclosed herein are inhibitors of Rho/MRTF/SRF-mediated gene transcription, and methods for their use in treating or preventing diseases such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
    本文披露了抑制Rho/MRTF/SRF介导的基因转录的抑制剂,以及它们在治疗或预防癌症和纤维化等疾病中的使用方法。具体地,本文披露了Formula (I)及其药用盐的化合物:其中取代基如所述。
查看更多